Maxime Luu

10PUBLICATIONS
19CO-AUTHORS
Molecular targetsMedical infection agents (incl. prions)Clinical pharmacology and therapeuticsMajor global burdens of diseaseEducational counselling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 08, 2026
Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature review.

|Jan 14, 2025
A phase II double-blind multicentre, placebo-controlled trial to assess the efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM study protocol.

Maxime Luu, Pierre Vabres, Aurélie Espitalier

|Jul 05, 2022
An update on drug-drug interactions associated with proton pump inhibitors.

Inès Ben Ghezala, Maxime Luu, Marc Bardou

|May 19, 2022
Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patients.

Simon Verdez, Quentin Thomas, Philippine Garret

|Mar 01, 2022
First use of Simulation in Therapeutic Patient Education (S-TPE) in adults with diabetes: a pilot study.

Christelle Pennecot, Maxime Luu, Claire Marchand

|Aug 13, 2021
Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study.

M Luu, P Vabres, H Devilliers

Pageof 2

Frequent Collaborators

4 joint publications

Marc Bardou

2 joint publications

Alan Barkun

2 joint publications

Laurence Faivre

1 joint publications

Christelle Pennecot